Related Experiment Video
Updated: Sep 28, 2025
10:25
Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
Published on: June 5, 2021
4.8K
A Faster, Novel Technique to Detect COVID-19 Neutralizing Antibodies
Wei-Huai Chiu1, Wei-Yi Kong1, Yu-Jang Su2,3,4,5
1Graduate Institute of Automation and Control, National Taiwan University of Science and Technology, Taipei, Taiwan.
Summary
A new lateral flow immunoassay coupled with a spectrometer (LFIA+S) accurately quantifies neutralizing antibodies (nAb). This affordable platform offers a rapid, efficient, and user-friendly method for assessing COVID-19 vaccine efficacy.
Area of Science:
- Immunology
- Vaccinology
- Biotechnology
Background:
- The COVID-19 pandemic necessitated rapid assessment of vaccine efficacy.
- Neutralizing antibody (nAb) levels are key indicators of vaccine effectiveness.
- Existing methods for nAb quantification can be time-consuming and costly.
Purpose of the Study:
- To develop and validate a novel platform for rapid, cost-effective, and efficient quantification of nAbs.
- To assess the performance of a lateral flow immunoassay kit coupled with a spectrometer (LFIA+S) against a gold standard assay.
- To establish the correlation between nAb levels and vaccine efficacy.
Main Methods:
- Collected 69 sera samples from unvaccinated and vaccinated individuals (1st and 2nd dose of AZ vaccine).
- Utilized cPass assays (ELISA) as the criterion standard for nAb detection.
- Employed a lateral flow immunoassay kit (LFIA) combined with a spectrometer (LFIA+S) for specimen analysis.
Main Results:
- Demonstrated high consistency between LFIA+S and cPass assays (Pearson's r =0.864; ICC=0.90138).
- The LFIA+S method showed a strong correlation with established nAb detection methods.
- Data confirmed the reliability and accuracy of the LFIA+S platform.
Conclusions:
- The LFIA+S platform is an affordable and efficient tool for quantifying nAbs.
- It exhibits strong correlation with cPass nAb detection kit results, indicating clinical utility.
- The platform's ease of use makes it suitable for non-experts, facilitating wider application.
